Center Variation in the Delivery of Indicated Late Preterm Births.
MedStar author(s):Citation: American Journal of Perinatology. 33(10):1008-16, 2016 AugPMID: 27120474Institution: MedStar Washington Hospital CenterDepartment: Obstetrics and Gynecology, Maternal-Fetal MedicineForm of publication: Journal ArticleMedline article type(s): Journal Article | Multicenter StudySubject headings: *Delivery, Obstetric/st [Standards] | *Fetal Membranes, Premature Rupture/ep [Epidemiology] | *Hypertension, Pregnancy-Induced/ep [Epidemiology] | *Placenta Previa/ep [Epidemiology] | *Premature Birth/ep [Epidemiology] | Adult | Female | Gestational Age | Humans | Infant, Newborn | Logistic Models | Pregnancy | Pregnancy Complications | Retrospective Studies | Risk Factors | United States/ep [Epidemiology] | Young AdultYear: 2016ISSN:
- 0735-1631
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 27120474 | Available | 27120474 |
Objective Evidence for optimal timing of delivery for some pregnancy complications at late preterm gestation is limited. The purpose of this study was to identify center variation of indicated late preterm births. Study design We performed an analysis of singleton late preterm and term births from a large U.S. retrospective obstetrical cohort. Births associated with spontaneous preterm labor, major congenital anomalies, chorioamnionitis, and emergency cesarean were excluded. We used modified Poisson fixed effects logistic regression with interaction terms to assess center variation of indicated late preterm births associated with four medical/obstetric comorbidities after adjusting for socio-demographics, comorbidities, and hospital/provider characteristics. Results We identified 150,055 births from 16 hospitals; 9,218 were indicated late preterm births. We found wide variation of indicated late preterm births across hospitals. The extent of center variation was greater for births associated with preterm premature rupture of membranes (risk ratio [RR] across sites: 0.45-3.05), hypertensive disorders of pregnancy (RR across sites: 0.36-1.27), and placenta previa/abruption (RR across sites: 0.48-1.82). We found less center variation for births associated with diabetes (RR across sites: 0.65-1.39). Conclusion Practice variation in the management of indicated late preterm deliveries might be a source of preventable late preterm birth. Copyright (c) Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
English
-
1
A randomized controlled trial of levosimendan to reduce mortality in high-risk cardiac surgery patients (CHEETAH): Rationale and design.
-
2
Molecule 16673-34-0: a new tool in our arsenal against inflammation.
-
3
Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: comparative effects of prasugrel and ticagrelor on platelet reactivity.
-
4
Accuracy of intravascular ultrasound and optical coherence tomography in identifying functionally significant coronary stenosis according to vessel diameter: A meta-analysis of 2,581 patients and 2,807 lesions.
-
5
Meta-Analysis of Diagnostic Performance of Coronary Computed Tomography Angiography, Computed Tomography Perfusion, and Computed Tomography-Fractional Flow Reserve in Functional Myocardial Ischemia Assessment Versus Invasive Fractional Flow Reserve. [Review]
-
6
Getting a job after cardiovascular fellowship: A reality check.
-
7
Evolving Electrocardiographic Indications for Emergent Reperfusion. [Review]
-
8
A dominant Limb Girdle Muscular Dystrophy with severe respiratory involvement; HNRNPLD as the new player
-
9
Assessing Risk in Patients with Stable Coronary Disease: When Should We Intensify Care and Follow-Up? Results from a Meta-Analysis of Observational Studies of the COURAGE and FAME Era. [Review]
-
10
Rationale and design of the Virginia Commonwealth University- Anakinra Remodeling Trial-3 (VCU-ART3): A Randomized Placebo-controlled Double-blinded Multicenter Study.
-
11
Natriuretic peptides in percutaneous coronary intervention: Aren't they all the same?.
-
12
Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST-Segment-Elevation Myocardial Infarction.
-
13
The utility of thrombus aspiration for NSTEMI: deja vu of aspiration for primary PCI.
-
14
Contrast-induced nephropathy and peripheral intervention: Who's keeping track?.
-
15
CD163+ macrophages promote angiogenesis and vascular permeability accompanied by inflammation in atherosclerosis.
-
16
C-reactive protein prior to percutaneous coronary intervention: do we still need to check the lipid panel?.
-
17
Radial versus femoral access in patients presenting with acute coronary syndrome in the post-matrix era: Still one size does not fit all.
-
18
Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy: Safety and Efficacy Results of a Phase II-A Randomized Trial.
-
19
The use of statins in patients with heart failure: more questions than answers.
-
20
Intraprocedural thrombotic events: What's the real cost?.
-
21
Biologics and Cardiovascular Disease.
-
22
Paracrine-Mediated Systemic Anti-Inflammatory Activity of Intravenously Administered Mesenchymal Stem Cells: A Transformative Strategy for Cardiac Stem Cell Therapeutics.
-
23
Mesenchymal Stem Cell Therapy for the Treatment of Heart Failure Caused by Ischemic or Non-ischemic Cardiomyopathy: Immunosuppression and Its Implications.
-
24
Persistent Inflammation, Stem Cell-Induced Systemic Anti-Inflammatory Effects, and Need for Repeated Stem Cell Injections: Critical Concepts Influencing Optimal Stem Cell Strategies for Treating Acute Myocardial Infarction and Heart Failure.
-
25
Natural Killer (NK) cells support pro-inflammation and contribute significantly to the deterioration of cardiac function following Acute Myocardial Infarction (AMI).
-
26
Large Animal Model Efficacy Testing Is Needed Prior to Launch of a Stem Cell Clinical Trial: An Evidence-Lacking Conclusion Based on Conjecture.
-
27
Mechanisms Contributing to the Progression of Ischemic and Nonischemic Dilated Cardiomyopathy: Possible Modulating Effects of Paracrine Activities of Stem Cells. [Review]
-
28
Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting about vorapaxar.
-
29
A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
-
30
Bone marrow-derived mesenchymal stem cells, grown in hypoxic conditions and injected intravenously, acutely engraft into ischemic murine myocardium, with later additional engraftment via redistribution from reservoir tissues
-
31
The effects of novel, bioresorbable scaffolds on coronary vascular pathophysiology. [Review]
-
32
Comparison of Acute Thrombogenicity for Magnesium versus Stainless Steel Stents in a Porcine Arteriovenous Shunt Model.
-
33
Efficacy and Safety of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin, Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization of Patients With Diabetes Mellitus.
-
34
A comparison of the ultrathin Orsiro Hybrid sirolimus-eluting stent with contemporary drug-eluting stents: A meta-analysis of randomized controlled trials.
-
35
Stent thrombosis is not increased following percutaneous coronary intervention in patients with non-insulin dependent diabetes mellitus taking metformin.
-
36
Intravenously-Delivered Mesenchymal Stem Cells: Systemic Anti-Inflammatory Effects Improve Left Ventricular Dysfunction in Acute Myocardial Infarction and Ischemic Cardiomyopathy.
-
37
Inflammation as a Driver of Adverse Left Ventricular Remodeling After Acute Myocardial Infarction. [Review]
-
38
Mesenchymal stem cells exposed to chronic hypoxia preferentially home to regions of myocardial injury following intravenous injection
-
39
Switching patients from clopidogrel to prasugrel in acute coronary syndrome: impact of the clopidogrel loading dose on platelet reactivity.
-
40
Comparison of Acute Thrombogenicity for Metallic and Polymeric Bioabsorbable Scaffolds: Magmaris Versus Absorb in a Porcine Arteriovenous Shunt Model.
-
41
Comparison of watchman device with new oral anti-coagulants in patients with atrial fibrillation: a network meta-analysis
-
42
Comparison of conventional and high-sensitivity troponin in patients with chest pain: a collaborative meta-analysis.
-
43
Current periprocedural myocardial infarction definitions are not surrogates for catheterization lab quality or clinical trial endpoints
-
44
WBC count at discharge is a strong predictor of all-cause mortality in patients with acute coronary syndrome that underwent percutaneous coronaryintervention
-
45
Safety of eptifibatide when added to bivalirudin during ST-segment elevation myocardial infarction.
-
46
Comparison of Watchman device with new oral anti-coagulants in patients with atrial fibrillation: A network meta-analysis.
-
47
Comparison of Platelet Reactivity in Black Versus White Patients With Acute Coronary Syndromes After Treatment With Ticagrelor.
-
48
Scaffold thrombosis following percutaneous coronary intervention with absorb bioresorbable vascular scaffold: a systematic review and meta-analysis
-
49
WBC count at discharge is a strong predictor of all-cause mortality in patients with acute coronary syndrome that underwent percutaneous coronaryintervention
-
50
Mortality in patients requiring pacemaker implantation following transcatheter aortic valve replacement: insights from a systematic review and meta-analysis. [Review]
-
51
Definitions of periprocedural myocardial infarction as surrogates for catheterization laboratory quality or clinical trial end points.
-
52
WBC count at discharge is a strong predictor of all-cause mortality in patients with acute coronary syndrome that underwent percutaneouscoronary intervention
-
53
Mortality in patients requiring pacemaker implantation following transcatheter aortic valvereplacement: insights from a systematic review and meta-analysis.
-
54
WBC count at discharge is a strong predictor of all-cause mortality in patients with acute coronary syndrome that underwent percutaneous coronaryintervention
-
55
WBC count at discharge is a strong predictor of all-cause mortality in patients with acute coronary syndrome that underwent percutaneous coronaryintervention
-
56
Comparison of treatment strategies for femoro-popliteal disease: A network meta-analysis.
-
57
Current application and bioavailability of drug-eluting stents. [Review]
-
58
Scaffold Thrombosis After Percutaneous Coronary Intervention With ABSORB Bioresorbable Vascular Scaffold: A Systematic Review and Meta-Analysis. [Review]
-
59
Comparison of outcomes of different revascularization strategies for femoro-popliteal disease: a network meta-analysis
-
60
A systematic review and collaborative meta-analysis to determine the incremental value of copeptin for rapid rule-out of acute myocardial infarction. [Review]
-
61
The choice of arterial access for percutaneous coronary intervention and its impact on outcome: An expert opinion perspective. [Review]
-
62
Comparison of heparin, bivalirudin, and different glycoprotein IIb/IIIa inhibitor regimens for anticoagulation during percutaneous coronary intervention: A network meta-analysis. [Review]
-
63
Comparison of Baseline Characteristics and Inhospital Outcomes of Patients and Use of Bare Metal Versus Drug-Eluting Stents During Percutaneous Coronary Intervention 2005 to 2015 at a Single Tertiary Hospital.
-
64
Active Versus Passive Anchoring Vascular Closure Devices Following Percutaneous Coronary Intervention: A Safety and Efficacy Comparative Analysis.
-
65
Comparison in Men Versus Women of Co-morbidities, Complications, and Outcomes After Transcatheter Aortic Valve Implantation for Severe Aortic Stenosis.
-
66
Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity.
-
67
Meta-Analysis of the Impact of Strut Thickness on Outcomes in Patients With Drug-Eluting Stents in a Coronary Artery.
-
68
Long-term outcomes in young women undergoing percutaneous coronary intervention for acute coronary syndromes
-
69
Does the disparity in baseline characteristics of patients undergoing transcatheter aortic valve replacement with 23 mm vs. 26 mm valves impact clinical outcome?.
-
70
A single center experience of Zilver PTX For femoro-popliteal lesions
-
71
Safety and efficacy of everolimus-eluting stents compared with first-generation drug-eluting stents in patients undergoing primary percutaneous coronary intervention.
-
72
Bivalirudin versus heparin for percutaneous coronary intervention: an updated meta-analysis of randomized controlled trials.
-
73
Long-term outcomes in young women undergoing percutaneous coronary intervention for acute coronary syndromes
-
74
Long-term experience with vascular brachytherapy for the treatment of refractory drug-eluting stent failure
-
75
Long-term experience with vascular brachytherapy for the treatment of refractory drug-eluting stent failure
-
76
Long-term experience with vascular brachytherapy for the treatment of refractory drug-eluting stent failure
-
77
Long-term outcomes in young women undergoing percutaneous coronary intervention for acute coronary syndromes
-
78
Long-term experience with vascular brachytherapy for the treatment of refractory drug-eluting stent failure
-
79
Long-term outcomes in young women undergoing percutaneous coronary intervention for acute coronary syndromes
-
80
Frequency of Angina Pectoris After Percutaneous Coronary Intervention and the Effect of Metallic Stent Type.
-
81
Optical coherence tomography-guided percutaneous coronary intervention compared with other imaging guidance: a meta-analysis.
-
82
A single center experience of Zilver PTX for femoro-popliteal lesions.
-
83
Impact of blood transfusions on short- and long-term mortality in patients who underwent transcatheter aortic valve implantation.
-
84
The effect of complete percutaneous revascularisation with and without intravascular ultrasound guidance in the drugeluting stent era.
-
85
Effect of Bleeding Risk on Type of Stent Used in Patients Presenting With Acute Coronary Syndrome.
-
86
Analysis of long-term survival following transcatheter aortic valve implantation from a single high-volume center.
-
87
Clinical presentation and outcomes of coronary in-stent restenosis across three stent generations.
-
88
Aortic valve ChromaFlo: a feasibility study of aortic regurgitation and effective annular aortic area assessment in a porcine model.
-
89
Utility of Invasive Electrophysiology Studies in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation.
-
90
Vascular access in critical limb ischemia. [Review]
-
91
Clinical presentation and outcomes of coronary in-stent restenosis across 3-stent generations.
-
92
Impact of right ventricular function on outcome of severe aortic stenosis patients undergoing transcatheter aortic valve replacement.
-
93
Response to letter regarding article, "Clinical presentation and outcomes of coronary in-stent restenosis across 3-stent generations".
-
94
Comparison of transradial and transfemoral access in patients undergoing percutaneous coronary intervention for complex coronary lesions.